Moxifloxacin Safety

Abstract

BackgroundMoxifloxacin, a fluoroquinolone antibiotic, is used for the treatment of respiratory tract, pelvic inflammatory disease, skin, and intra-abdominal infections. Its safety profile is considered favorable in most reviews but has been challenged with respect to rare but potentially fatal toxicities (e.g. hepatic, cardiac, or skin reactions).ObjectiveTo analyze and compare the safety profile of moxifloxacin versus comparators in the entire clinical database of the manufacturer.SettingData on the valid-for-safety population from phase II–IV actively controlled studies (performed between 1996 and 2010) were analyzed. Studies were either double blind (n = 22 369) or open label (n = 7635) and included patients with indications that have been approved in at least one country [acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia, uncomplicated pelvic inflammatory disease, complicated and uncomplicated skin and skin structure infections, and complicated intra-abdominal infections] (n = 27 824) and patients with other indications (n = 2180), using the recommended daily dose (400 mg) and route of administration (oral, intravenous/oral, intravenous only). The analysis included patients at risk (age ≥65 years, diabetes mellitus, renal impairment, hepatic impairment, cardiac disorders, or body mass index <18 kg/m2). Patients with known contraindications were excluded from enrollment by study protocol design, but any patient having entered a study, even if inappropriately, was included in the analysis.Main Outcome MeasureCrude incidences and relative risk estimates (Mantel-Haenszel analysis) of patients with any adverse event (AE), adverse drug reaction (ADR), serious AE (SAE), serious ADR (SADR), treatment discontinuation due to an AE or ADR, and fatal outcomes related to an AE or ADR.ResultsOverall incidence rates of AEs were globally similar in the moxifloxacin and comparator groups. By filtering the data for differences in disfavor of moxifloxacin (i) at ≥2.5% for events with an incidence ≥2.5% or at ≥2-fold for events with an incidence <2.5% in one or both groups and (ii) affecting ≥10 patients in either group, we observed slightly more (i) AEs in double-blind intravenous-only and open-label oral studies, (ii) SAEs in double-blind intravenous-only studies, (iii) ADRs and SADRs in open-label oral studies, (iv) SADRs in open-label intravenous/oral studies, and (v) premature discontinuation due to AEs in open-label intravenous-only studies. The actual numbers of SADRs (in all studies) were small, with clinically relevant differences noted only in intravenous/oral studies and mainly driven by ‘gastrointestinal disorders’ (15 versus 7 patients) and ‘changes observed during investigations’ (23 versus 7 patients [asymptomatic QT prolongation: 11 versus 4 patients in double-blind studies]). Analysis by comparator (including another fluoroquinolone) did not reveal medically relevant differences, even in patients at risk. Incidence rates of hepatic disorders, tendon disorders, clin...

Moxifloxacin in Complicated Skin and Skin Structure Infections (cSSSIs): A Prospective, International, Non-Interventional, Observational Study

“…In this respect, no unexpected safety events were seen in the ARTOS study. The nature of AEs, including serious AEs, was consistent with the established safety profile of moxifloxacin as described recently [26]. …”

Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development

“…Notably, moxifloxacin, a well-known QT prolonger, exhibited a mid-range TdP(−) probability of 0.46. While CredibleMeds ® classifies moxifloxacin as TdP(+), this drug is considered to be relatively safe as evidenced by its extensive use as a positive control for thorough QT (TQT) trials [ 40 , 41 ]. Therefore, the probability predicted by the Cardiac Risk Algorithm seems appropriate, and suggests that moxifloxacin could be classified as a middle risk compound.…”

A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia

“…MFLX is specifically approved for treating infections of the respiratory tract [i.e. acute bacterial sinusitis, the acute exacerbation of chronic bronchitis and community-acquired pneumonia (CAP)] ( 3 ). Due to its spectrum of activity, it is also recommended for the treatment of hospital-acquired pneumonia (HAP) in selected patients ( 4 ).…”